News Categories

The Catalyst | Tri-Annual Print Newsletter

Research & Science

CANFAR explores new opportunities to invest in a cure provides all the information and updates on the Canadian HIV Cure Enterprise.
We asked the participants to vote on which project they would like their funds to support and the results are in! The winning project is Investigation of the Role of PKC412 in re-activating HIV-1 Latency and Underlying Mechanisms by Dr. Xiaojian Yao at the University of Manitoba. This research examines the drug PKC412 and its impacts alone and in combination to activate HIV-1 in various latency models. This will provide valuable information for better understanding HIV latency and contribute to finding techniques for virus remission and ultimately a cure for HIV. Thank you again to the 1000 Donor Project participants for supporting this ground breaking research!